Direct Answer
Myristoyl Pentapeptide-17 is a lab-made lipopeptide used in eyelash and eyebrow products and marketed to condition lashes by stimulating keratin genes. What we don't know: we could not find any independent study or clinical trial of it — the lash claims are supplier marketing, and no sample-size data exist.
Summary Table
Evidence Level
Low
AI Summary
Myristoyl Pentapeptide-17 is a synthetic lipopeptide (myristic acid on a pentapeptide) used in eyelash/eyebrow conditioning products. Suppliers (e.g., Flychem, COSROMA) market it as stimulating keratin genes in lash follicles for the appearance of longer, fuller lashes. Evidence is low: we found no independent study or clinical trial, supplier pages state no sample size or efficacy percentages, and the CIR pentapeptide safety assessment names Myristoyl Pentapeptide-4 (not -17). Typical supplier-stated use is 0.01-0.1% (assay 1000 ppm). It should be read as a supplier-marketed cosmetic peptide with no independent evidence.
Key Information
Classification
Key Takeaways
- What we don't know: there is no independent study or trial we could find — lash claims are supplier marketing with no sample size
- Myristoyl Pentapeptide-17 is a cosmetic lash/brow peptide marketed to stimulate keratin genes
- Supplier-stated use is 0.01-0.1% (assay 1000 ppm); it is not a prescription lash-growth drug
Scientific Overview
In Plain English
Myristoyl Pentapeptide-17 is a lab-made peptide added to lash and brow serums and marketed to make lashes look longer and fuller by acting on keratin. We could not find any independent study or trial of it; the claims come from suppliers, who publish no study size or numbers.
Scientific Details
Myristoyl Pentapeptide-17 is a myristoylated pentapeptide used as a cosmetic lash-conditioning ingredient. Suppliers describe a mechanism of stimulating keratin gene expression in the lash follicle. No independent peer-reviewed study or clinical trial was found; supplier materials provide a stated use concentration (0.01-0.1%; assay 1000 ppm) but no efficacy figures or sample sizes. It is distinct from prescription lash-growth drugs such as bimatoprost.
How It Works
Suppliers state that Myristoyl Pentapeptide-17 stimulates keratin genes in the lash follicle to support lash appearance. This is a supplier-stated mechanism; no independent study confirming it was found.
Mechanism of Action
Supplier-stated keratin-gene stimulation
limited
Suppliers (e.g., Flychem MyriLash) state the peptide stimulates keratin genes in lash follicles. Supplier-stated; no independent confirmation was found.
Evidence Level
Human Evidence
No independent human study or clinical trial was found; supplier materials report no sample size or efficacy figures.
Limitations
Beyond chemical identity, all claims are supplier marketing. No independent study exists, and the CIR pentapeptide assessment does not name Myristoyl Pentapeptide-17.
Why This Grade
Graded low: the only verifiable fact is chemical identity (PubChem). The keratin/lash mechanism and use concentration are supplier-stated (e.g., Flychem), with no numeric efficacy claims and no sample size. No independent study or clinical trial was found, and the CIR "Pentapeptides" safety assessment names Myristoyl Pentapeptide-4, not -17, so no CIR citation applies.
Frequently Asked Questions
What is Myristoyl Pentapeptide-17?
Myristoyl Pentapeptide-17 is a synthetic lipopeptide used in eyelash and eyebrow products and marketed to condition lashes by stimulating keratin genes.
Does Myristoyl Pentapeptide-17 grow eyelashes?
We could not find any independent study or clinical trial. The lash claims come from suppliers, who publish no sample size or efficacy figures. It is a cosmetic conditioning ingredient, not a proven lash-growth treatment.
Is Myristoyl Pentapeptide-17 like Latisse (bimatoprost)?
No. Bimatoprost (Latisse) is an FDA-approved prescription drug shown in trials to lengthen lashes. Myristoyl Pentapeptide-17 is an unproven cosmetic peptide with no independent studies; they work differently and are not equivalent.
References
- MyriLash (Myristoyl Pentapeptide-17, 1000 ppm) — manufacturer product information (Flychem). (Supplier product page (Flychem). Marketing, not an independent study. Cited only for the supplier-stated mechanism (keratin-gene stimulation) and use concentration (0.01-0.1%; assay 1000 ppm); the page states no efficacy figures or sample size.)Supplier-stated mechanism and use concentration only — no efficacy figures.Supplier DataView source →
Alternative Names
- MyriLash
Risks & Safety
- Not an approved medicine; a cosmetic ingredient with the usual patch-test considerations, especially near the eyes
- No independent efficacy or safety study specific to Myristoyl Pentapeptide-17 was found
- Not a substitute for, and mechanistically unrelated to, prescription lash-growth drugs (e.g., bimatoprost)
- Material from research-chemical vendors is not quality-controlled
Claim Boundaries
ION BLUE is an educational research aggregator. This content summarizes published scientific literature. It is not medically reviewed, is not medical advice, and is not a recommendation to use any substance. Consult a licensed healthcare provider. This entry does not assert that Myristoyl Pentapeptide-17 grows or lengthens eyelashes in people; such claims are supplier marketing and no independent study was found. It is not a prescription lash-growth drug.
This page summarizes published research and is for informational purposes only; it is not medical advice.